Top Markets
Coin of the day
BioAge Labs Inc. BioAge Labs Inc.

BioAge Labs Inc.

BIOA
Clasificación en acciones #15401
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops... BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Precio por acción
$9.50
Capitalización bursátil
$357.67M
Cambio (1 día)
0.00%
Cambio (1 año)
92.70%
País
US
Comercio BioAge Labs Inc. (BIOA)

Categoría

Ratio P/S de BioAge Labs Inc. (BIOA)
Ratio P/S al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de BioAge Labs Inc., el ratio P/S actual (TTM) es 0. Al final de 2026, el ratio P/S era 0.
Historial del ratio P/S de BioAge Labs Inc. desde 2026 hasta 2026
Ratio P/S al final de cada año
Año Ratio P/S Cambiar
Not enough data for the provided dates.
Ratio P/S de empresas similares o competidoras
Empresa Ratio P/S Diferencia del ratio P/S País
10.95 -
US
12.19 -
NL
24.99 -
US
3.75 -
AU
- -
CH